A/Prof David van der Poorten
Dr Roslyn Vongsuvanh
  Prof Golo Ahlenstiel
Dr Way Siow

Appointments & Enquiries:  (02) 8711 0160

Prof Golo Ahlenstiel

 

Publications

Prof Ahlenstiel has published widely in the medical literature and continues to be active in teaching and research.

Summaries of his research output can be found on:

 

Google Scholar

Screen Shot 2017 04 26 at 4.21.10 PM

Research Gate

Golo Rgate

 

 

Endoscopic resection of large duodenal and papillary lateral spreading lesions is clinically and economically advantageous compared with surgery.

Klein A, Ahlenstiel G, Tate DJ, Burgess N, Richardson A, Pang T, Byth K, Bourke MJ.

Endoscopy. 2017 Apr 4. doi: 10.1055/s-0043-105484. [Epub ahead of print]

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.

O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR.

Genes Immun. 2016 Sep;17(6):328-34. doi: 10.1038/gene.2016.27. Epub 2016 Jun 16.

Validated computed cleansing score for video capsule endoscopy.

Klein A, Gizbar M, Bourke MJ, Ahlenstiel G.

Dig Endosc. 2016 Jul;28(5):564-9. doi: 10.1111/den.12599. Epub 2016 Jan 21.

FibroGENE: A gene-based model for staging liver fibrosis.

Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Nattermann J, Riordan S, Miele L, Kelaeng KS, Ampuero J, Ahlenstiel G, McLeod D, Powell E, Liddle C, Douglas MW, Booth DR, George J; International Liver Disease Genetics Consortium (ILDGC)..

J Hepatol. 2016 Feb;64(2):390-8. doi: 10.1016/j.jhep.2015.11.008. Epub 2015 Dec 1.

Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report.

Garcia MC, Ahlenstiel G, Mahajan H, van der Poorten D.

J Med Case Rep. 2015 Oct 1;9:210. doi: 10.1186/s13256-015-0705-6.

Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).

Dold L, Ahlenstiel G, Althausen E, Luda C, Schwarze-Zander C, Boesecke C, Wasmuth JC, Rockstroh JK, Spengler U.

PLoS One. 2015 Aug 4;10(8):e0134158. doi: 10.1371/journal.pone.0134158. eCollection 2015.

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC)..

Nat Commun. 2015 Mar 5;6:6422. doi: 10.1038/ncomms7422.

Feasibility and Safety of Overtubes for PEG-Tube Placement in Patients with Head and Neck Cancer.

Musumba CO, Hsu J, Ahlenstiel G, Tutticci NJ, Nanda KS, van der Poorten D, Lee EY, Kwan V.

Gastroenterol Res Pract. 2015;2015:612610. doi: 10.1155/2015/612610. Epub 2015 Apr 21.

Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response.

O'Connor KS, George J, Booth D, Ahlenstiel G.

World J Gastroenterol. 2014 Dec 21;20(47):17830-8. doi: 10.3748/wjg.v20.i47.17830. Review.

Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon.

Ahlenstiel G, Hourigan LF, Brown G, Zanati S, Williams SJ, Singh R, Moss A, Sonson R, Bourke MJ; Australian Colonic Endoscopic Mucosal Resection (ACE) Study Group..

Gastrointest Endosc. 2014 Oct;80(4):668-76. doi: 10.1016/j.gie.2014.04.015. Epub 2014 Jun 7.

Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.

Werner JM, Serti E, Chepa-Lotrea X, Stoltzfus J, Ahlenstiel G, Noureddin M, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2014 Oct;60(4):1160-9. doi: 10.1002/hep.27092. Epub 2014 Aug 13.

IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis.

O'Connor KS, Ahlenstiel G, Suppiah V, Schibeci S, Ong A, Leung R, van der Poorten D, Douglas MW, Weltman MD, Stewart GJ, Liddle C, George J, Booth DR.

Innate Immun. 2014 Aug;20(6):598-605. doi: 10.1177/1753425913503385. Epub 2013 Sep 17.

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G.

J Hepatol. 2014 Aug;61(2):235-41. doi: 10.1016/j.jhep.2014.03.039. Epub 2014 Apr 24.

A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.

Beard MR, Ffrench R, Gowans EJ, Helbig KJ, Eyre NM, Douglas MM, Grebely J, Ahlenstiel G, Locarnini S, George J, Shackel NA, White PA, Thompson AJ, Drummer HE.

Gastroenterology. 2014 Jul;147(1):e1-4. doi: 10.1053/j.gastro.2014.05.022. Epub 2014 May 23. No abstract available. 

Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection.

Eslam M, Booth DR, George J, Ahlenstiel G.

World J Gastroenterol. 2013 Nov 7;19(41):7055-61. doi: 10.3748/wjg.v19.i41.7055.

PMID:

The natural killer cell response to HCV infection.

Ahlenstiel G.

Immune Netw. 2013 Oct;13(5):168-76. doi: 10.4110/in.2013.13.5.168. Epub 2013 Oct 26. Review.

CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection.

Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Nattermann J, Mueller T, Riordan S, Stewart GJ, George J, Booth DR, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC)..

Genes Immun. 2013 Jul-Aug;14(5):286-90. doi: 10.1038/gene.2013.15. Epub 2013 Apr 18.

Pharmacogenomics of hepatitis C infections: personalizing therapy.

Booth DR, Ahlenstiel G, George J.

Genome Med. 2012 Dec 26;4(12):99. doi: 10.1186/gm400. eCollection 2012. Review.

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?

Ahlenstiel G, Booth DR, George J.

Antivir Ther. 2012;17(6 Pt B):1163-70. doi: 10.3851/IMP2427. Epub 2012 Oct 5. Review.

Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.

Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B.

Hepatology. 2012 Jan;55(1):39-48. doi: 10.1002/hep.24628. Epub 2011 Nov 14.

Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.

Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B.

Gastroenterology. 2011 Oct;141(4):1231-9, 1239.e1-2. doi: 10.1053/j.gastro.2011.06.069. Epub 2011 Jul 7.

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.

Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G, Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY, Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC)..

PLoS Med. 2011 Sep;8(9):e1001092. doi: 10.1371/journal.pmed.1001092. Epub 2011 Sep 13.

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort.

Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR; International Hepatitis C Genetics Consortium (IHCGC)..

Genome Med. 2011 Aug 31;3(8):57. doi: 10.1186/gm273.

S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.

Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, Titerence R, Koh C, Cherepanov V, Heller T, Ghany MG, Park Y, Hoofnagle JH, Liang TJ.

Gastroenterology. 2011 Mar;140(3):830-9. doi: 10.1053/j.gastro.2010.09.010. Epub 2010 Sep 17.

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

Ahlenstiel G, Booth DR, George J.

J Gastroenterol. 2010 Sep;45(9):903-10. doi: 10.1007/s00535-010-0287-4. Epub 2010 Jul 16. Review.

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.

Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S, Rockstroh JK.

Eur J Med Res. 2010 Mar 30;15(3):102-11.

Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, Ghany MG, Hoofnagle JH, Liang TJ, Heller T, Rehermann B.

Gastroenterology. 2010 Jan;138(1):325-35.e1-2. doi: 10.1053/j.gastro.2009.08.066. Epub 2009 Sep 10.

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J.

Nat Genet. 2009 Oct;41(10):1100-4. doi: 10.1038/ng.447. Epub 2009 Sep 13.

Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.

Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Schott E, Weich V, Schlosser B, Wasmuth HE, Lammert F, Berg T, Schreier E.

Infect Genet Evol. 2009 Sep;9(5):847-52. doi: 10.1016/j.meegid.2009.05.002. Epub 2009 May 14.

Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis.

Mix H, Weiler-Normann C, Thimme R, Ahlenstiel G, Shin EC, Herkel J, David CS, Lohse AW, Rehermann B.

Gastroenterology. 2008 Dec;135(6):2107-18. doi: 10.1053/j.gastro.2008.07.029. Epub 2008 Jul 31.

The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.

Nattermann J, Vogel M, Nischalke HD, Danta M, Ahlenstiel G, Michalk M, Sauerbruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS..

AIDS. 2008 Jul 11;22(11):1287-92. doi: 10.1097/QAD.0b013e3282f85daa.

Identification of new major histocompatibility complex-A, -B, -C alleles in chimpanzees (Pan troglodytes).

Caggiari L, De Zorzi M, Ahlenstiel G, Rehermann B, De Re V.

Tissue Antigens. 2008 Jul;72(1):79-83. doi: 10.1111/j.1399-0039.2008.01061.x. Epub 2008 May 20.

Description of two new major histocompatibility complex (MHC) class II DRB1 [Pan troglodytes (Patr)-DRB1] alleles.

De Zorzi M, Caggiari L, Ahlenstiel G, Rehermann B, De Re V.

Tissue Antigens. 2008 May;71(5):490-2. doi: 10.1111/j.1399-0039.2008.01027.x. Epub 2008 Mar 11.

Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses.

Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B.

J Clin Invest. 2008 Mar;118(3):1017-26. doi: 10.1172/JCI32400.

Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level.

Ahlenstiel G, Roomp K, Däumer M, Nattermann J, Vogel M, Rockstroh JK, Beerenwinkel N, Kaiser R, Nischalke HD, Sauerbruch T, Lengauer T, Spengler U; Kompetenznetz HIV/AIDS..

Clin Vaccine Immunol. 2007 Oct;14(10):1266-73. Epub 2007 Aug 22.

The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.

Ahlenstiel G, Nischalke HD, Bueren K, Berg T, Vogel M, Biermer M, Grünhage F, Sauerbruch T, Rockstroh J, Spengler U, Nattermann J.

J Hepatol. 2007 Sep;47(3):348-55. Epub 2007 May 24.

Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion.

Vogel M, Lichterfeld M, Kaufmann DE, Mui SK, Altfeld M, Voigt E, Ahlenstiel G, Kupfer B, Walker B, Spengler U, Rockstroh JK.

Eur J Med Res. 2006 Jul 31;11(7):273-8.

Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study.

Ahlenstiel G, Iwan A, Nattermann J, Bueren K, Rockstroh JK, Brackmann HH, Kupfer B, Landt O, Peled A, Sauerbruch T, Spengler U, Woitas RP.

World J Gastroenterol. 2005 Dec 28;11(48):7631-8.

Hepatitis C virus and the threshold of natural killer cell inhibition.

Ahlenstiel G, Rehermann B.

Hepatology. 2005 Mar;41(3):675-7. No abstract available. 

The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells.

Nattermann J, Nischalke HD, Hofmeister V, Ahlenstiel G, Zimmermann H, Leifeld L, Weiss EH, Sauerbruch T, Spengler U.

Am J Pathol. 2005 Feb;166(2):443-53.

HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells.

Nattermann J, Nischalke HD, Hofmeister V, Kupfer B, Ahlenstiel G, Feldmann G, Rockstroh J, Weiss EH, Sauerbruch T, Spengler U.

Antivir Ther. 2005;10(1):95-107.

Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5.

Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U.

J Viral Hepat. 2004 Nov;11(6):519-26.

Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.

Mueller T, Mas-Marques A, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U, Wiedenmann B, Schreier E, Berg T.

J Hepatol. 2004 Oct;41(4):652-8.

CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response?

Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U.

J Antimicrob Chemother. 2004 Jun;53(6):895-8. Epub 2004 May 5.

Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.

Ahlenstiel G, Berg T, Woitas RP, Grünhage F, Iwan A, Hess L, Brackmann HH, Kupfer B, Schernick A, Sauerbruch T, Spengler U.

J Hepatol. 2003 Aug;39(2):245-52.

[Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?].

Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offergeld R, Sauerbruch T, Spengler U.

Dtsch Med Wochenschr. 2002 Sep 6;127(36):1807-12. German. 

Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.

Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offergeld R, Sauerbruch T, Spengler U.

Gastroenterology. 2002 Jun;122(7):1721-8.